EFFECT OF RITUXIMAB ON THE BLOOD CHOLESTEROL TRANSPORT SYSTEM IN PATIENTSWITH RHEUMATOID ARTHRITIS

Objective: To study the time course of changes in the indices of the blood lipid spectrum in patients with rheumatoid arthritis (RA) treated with rituximab during a 24-week follow-up. Subjects and methods. The study enrolled 39 patients (36 females and 3 males) with a valid diagnosis of RA; their me...

書誌詳細
出版年:	Научно-практическая ревматология
主要な著者:	Tatyana Valentinovna Popkova, D S Novikova, O G Lineva, A A Novikov, E N Aleksandrova, E L Nasonov
フォーマット:	論文
言語:	ロシア語
出版事項:	IMA PRESS LLC 2010-08-01
主題:	rheumatoid arthritis chronic inflammation blood lipid spectrum rituximab
オンライン･アクセス:	https://rsp.mediar-press.net/rsp/article/view/1076

類似資料

ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS
著者:: A. A. Novikov, 等
出版事項: (2011-06-01)

CHANGES IN HEART RATE, HEART RATE VARIABILITY AND QT INTERVAL IN WOMEN WITH RHEUMATOID ARTHRITIS DURING RITUXIMAB TREATMENT
著者:: D. S. Novikova, 等
出版事項: (2014-06-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
著者:: A. S. Avdeeva, 等
出版事項: (2021-09-01)

Combination therapy for rheumatoid arthritis with rituximab and leflunomide(preliminary results of the Russian ARBITR Registry)
著者:: Evgeniy L'vovich Nasonov, 等
出版事項: (2011-02-01)

The Impact of Rituximab Therapy on the Chromosomes of Patients with Rheumatoid Arthritis
著者:: Šekib Sokolović, 等
出版事項: (2010-05-01)

Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis
著者:: Aleksandr Vital'evich Volkov, 等
出版事項: (2010-12-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
著者:: E. L. Nasonov, 等
出版事項: (2016-12-01)

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
著者:: M. A. Korolev, 等
出版事項: (2021-01-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
著者:: E. L. Nasonov, 等
出版事項: (2017-09-01)

PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
著者:: Volkava M. V.
出版事項: (2019-11-01)

EFFECT OF RITUXIMAB ON CARDIAC ELECTROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
著者:: L. I. Feiskhanova
出版事項: (2018-11-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
著者:: A. S. Avdeeva, 等
出版事項: (2018-11-01)

Administration of monoclonal antibodies to b-lymphocytes (rituximab) in rheumatoid arthritis in Russia
著者:: E L Nasonov, 等
出版事項: (2008-08-01)

Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis
著者:: Anastasia Sergeyevna Avdeyeva, 等
出版事項: (2012-08-01)

Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis
著者:: A. S. Avdeeva, 等
出版事項: (2019-07-01)

THE EFFICACY AND SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: NEW EVIDENCE
著者:: D. A. Kusevich, 等
出版事項: (2017-09-01)

Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)
著者:: A. S. Avdeeva, 等
出版事項: (2019-03-01)

Association between Interleukin-6 Levels, Rituximab Response, and Disease Activity in Patients with Rheumatoid Arthritis
著者:: Aya Fawzi Talib, 等
出版事項: (2025-08-01)

Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study
著者:: Suhel Gabriele Al Khayyat, 等
出版事項: (2021-08-01)

Dynamics of lymphocyte subpopulations, CD4+CD25+CD127- T regulatory cells in patients with rheumatoid arthritis during therapy with the rituximab biosimilar Acellbia
著者:: A. S. Avdeeva, 等
出版事項: (2020-05-01)

RITUXIMAB THERAPY MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS HROUGH PERIPHERAL BLOOD GENE EXPRESSION ANALYSIS
著者:: E. V. Chetina, 等
出版事項: (2014-06-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
著者:: D. A. Kusevich, 等
出版事項: (2019-01-01)

Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis
著者:: A Finckh, 等
出版事項: (2010-07-01)

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar
著者:: A. S. Avdeeva, 等
出版事項: (2022-06-01)

Efficacy, Safety and Predictors of Response to Rituximab in Treatment of Iraqi Patients with Active Rheumatoid Arthritis
著者:: Sarah Tareq Abdulazeez, 等
出版事項: (2019-06-01)

A Rare Case of Disseminated Histoplasmosis with Oral Manifestations in a Rheumatoid Arthritis Patient Treated with Rituximab Diagnostic and Management Challenges – A Review
著者:: Shruti Bajad, 等
出版事項: (2020-01-01)

Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis
著者:: Evgenija Mihajloska, 等
出版事項: (2024-06-01)

Quality of life in patients with rheumatoid arthritis during rituximab therapy
著者:: Tatiana Alekseyevna Raskina, 等
出版事項: (2013-06-01)

Acquired hemophilia A treated with rituximab in a 62-year-old female with rheumatoid arthritis: a case-based review
著者:: D. Mohamadzadeh, 等
出版事項: (2023-12-01)

Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab
著者:: Mie Jin Lim, 等
出版事項: (2023-11-01)

TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
著者:: A V Bezgin, 等
出版事項: (2011-08-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
著者:: D. A. Kusevich, 等
出版事項: (2022-06-01)

Role of blood cholesterol transport system disturbances in atherosclerosis development in rheumatoid arthritis
著者:: T. V. Popkova, 等
出版事項: (2007-10-01)

Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
著者:: Narendra Maharaj, 等
出版事項: (2024-12-01)

Comparison of rituximab vs. cyclophosphamide in rheumatoid arthritis-associated interstitial lung disease and its correlation with spirometry
著者:: Mohammed Abdullah Saleem, 等
出版事項: (2024-12-01)

Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
著者:: Elena Vasilyevna Udachkina, 等
出版事項: (2013-10-01)

THE ROLE OF LABORATORY BIOMARKERS IN PREDICTING THE EFFICIENCY OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: NEW EVIDENCE
著者:: A. S. Avdeeva, 等
出版事項: (2017-07-01)

Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study
著者:: L. Bazzichi, 等
出版事項: (2014-11-01)

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AS A COMPLICATION OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS (A CASE REPORT)
著者:: I. B. Bashkova, 等
出版事項: (2018-09-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
著者:: Elena Nikolayevna Aleksandrova, 等
出版事項: (2012-02-01)